Cancer Drug Shortage Hits India: Patients Face Treatment Delays

India is facing a severe nationwide shortage of the vital chemotherapy drugs cisplatin and carboplatin. These drugs are crucial for treating various solid tumors and blood cancers, including ovarian, lung, and testicular cancers. The scarcity stems from a confluence of factors: a sharp increase in global platinum prices, the core raw material, and disruptions to shipping routes in West Asia. These issues have made existing price-capped manufacturing rates financially unviable for many domestic producers, leading some to halt or slow production.

While some government hospitals have managed to stabilize supplies, private facilities are reporting significant drug deficits, with shortages ongoing for approximately seven months. Patients are experiencing delays, treatment interruptions, and increased stress due to this crisis. The therapeutic role of cisplatin and carboplatin is difficult to replace, especially in concurrent chemoradiation for cervical and head and neck cancers, where weekly cisplatin is vital for treatment efficacy. Such delays could compromise patient outcomes, particularly in curative-intent cancers.

To address the situation, the government recently invoked special clauses to temporarily raise the price cap for cisplatin and carboplatin by 50%. This measure aims to incentivize domestic manufacturing and restock depleted supply chains. Experts suggest that India needs a long-term drug security framework, including strategic reserves, diversified manufacturing, and an early-warning system to prevent future shortages, given the country's high annual cancer diagnosis rate of over 1.5 million new cases.